Post-Hoc, Exploratory Subgroup Analyses: Intention to Receive COVID-19 Vaccination and Reported Barriers Among White, Black, Hispanic, and Asian Respondents
| Variable | N (%)* | |||
|---|---|---|---|---|
| White | Black | Hispanic | Asian | |
| If a vaccine for novel coronavirus (COVID-19) receives Food and Drug Administration (FDA) approval, when do you intend to become vaccinated? | ||||
| Within the first month of approval | 1152 (38.5) | 17 (13.6) | 56 (37.1) | 61 (40.1) |
| 1 to 3 months after approval | 675 (22.6) | 14 (11.2) | 34 (22.5) | 44 (28.9) |
| 4 to 6 months after approval | 333 (11.1) | 12 (9.6) | 19 (12.6) | 20 (13.2) |
| 7 to 12 months after approval | 197 (6.6) | 17 (13.6) | 13 (8.6) | 9 (5.9) |
| More than 1 year (12 months) after approval | 355 (11.9) | 29 (23.2) | 18 (11.9) | 16 (10.5) |
| I do not intend to be vaccinated | 278 (9.3) | 36 (28.8) | 11 (7.3) | 2 (1.3) |
| No response | 10 | 1 | 1 | 0 |
| Which of the following concerns influence your decision to delay vaccination or to not receive vaccination?† | ||||
| The vaccine will not be safe | 1015 (55.2) | 64 (59.3) | 37 (38.9) | 56 (61.5) |
| The vaccine will not be effective | 693 (37.7) | 38 (35.2) | 34 (35.8) | 29 (31.9) |
| I may be allergic to the vaccine | 186 (10.1) | 23 (21.3) | 4 (4.2) | 18 (19.8) |
| Risk of vaccination is more than the benefit | 568 (30.9) | 40 (37.0) | 25 (26.3) | 24 (26.4) |
| Short-term side effects (painful injection, muscle pain, feeling unwell the day of the injection, etc.) | 129 (7.0) | 18 (16.7) | 4 (4.2) | 11 (12.1) |
| Long-term side effects of the vaccine | 1052 (57.2) | 69 (63.9) | 49 (51.6) | 43 (47.3) |
| The vaccine will be too expensive | 229 (12.5) | 8 (7.4) | 15 (15.8) | 15 (16.5) |
| I will not have time to get the vaccine | 69 (3.8) | 0 (0.0) | 9 (9.5) | 5 (5.5) |
| The vaccine will give me novel coronavirus (COVID-19) | 81 (4.4) | 16(14.8) | 5 (5.3) | 3 (3.3) |
| Personal religious, moral or ethical reasons | 124 (6.7) | 21 (19.4) | 3 (3.2) | 3 (3.3) |
| Already been infected with novel coronavirus (COVID-19) | 45 (2.4) | 2 (1.9) | 0 (0.0) | 1 (1.1) |
| Other | 266 (14.5) | 16 (14.8) | 4 (4.2) | 11 (12.1) |